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INTRODUCTION  
 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity 
and mortality throughout the world. Many people suffer from this disease for years and 
die prematurely from it or its complications. COPD is the fourth leading cause of death in 
the world9 and further increases in its prevalence and mortality can be predicted in the 
coming decades8. 
 
In the definition of COPD, the phrase “preventable and treatable” has been incorporated 
following the ATS/ERS recommendations to recognize the need to present a positive 
outlook for patients, to encourage the health care community to take a more active role in 
developing programs for COPD prevention and to stimulate effective management 
programs to treat those with the disease2,8  
 
The chronic airflow limitation characteristic of COPD is caused by a mixture of small 
airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the 
relative contributions of which vary from person to person.8 COPD has a variable natural 
history and not all individuals follow the same course7. However, COPD is generally a 
progressive disease, especially if a patient's exposure to noxious agents continues1,8. The 
impact of COPD on an individual patient depends on the severity of symptoms 
(especially breathlessness and decreased exercise capacity) systemic effects, and any 
comorbidities the patient may have not just on the degree of airflow limitation. 
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Worldwide, cigarette smoking is the most commonly encountered risk factor for COPD, 
although in many countries, air pollution resulting from the burning of wood and other 
biomass fuels has also been identified as a COPD risk factor.8 
The prevalence of COPD reported in different population based studies from India is 
highly variable7. The prevalence rates in male subjects of 2.12% to 9.4% in studies 
reported from North are generally higher than 1.4% to 4.08% reported from South India. 
The respective ranges for female subjects vary from 1.33% to 4.9% from North and from 
2.55% to 2.7% from South India. For epidemiological assessment, the rounded-off 
median prevalence rates were assessed as 5 percent for male and 2.7 percent for female 
subjects of over 30 years of age. The disease is distinctly more common in males. The 
male to female ratio had varied from 1.32:1 to 2.6:1 in different studies with a median 
ratio of 1.6:17 
Spirometry provides quick assessment of expiratory functions that correlate with FEV1 & 
also enable us to differentiate between restrictive, obstructive & proximal air way 
disease8. The combination of Pulse oximetry & Spirometry give valuable information 
about patient's status. Long standing COPD disease can lead to exertional & nocturnal 
hypoxemia. Frequent Hypoxic episodes & nocturnal hypoxemia leads to the development 
of secondary polycythemia & its consequences.10 
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AIM OF THE STUDY 
To study age and sex distribution in COPD patients  
To study the risk factors in COPD patients. 
To study about the duration and influence of smoking habit in the development& 
progression of COPD. 
To study the presenting symptoms in COPD patients  
To study the physical signs in COPD patients 
To Study the Pulse oximetry values to detect hypoxemia, prognosis, to plan oxygen 
therapies in chronic obstructive pulmonary disease. 
To study the correlation between Hemoglobin level and severity of disease. 
To study the correlation between Hematocrit level and severity of disease  
To assess the severity of chronic obstructive pulmonary disease 
by the pulmonary function tests. 
To study chest x-ray findings, ECG findings in COPD patients 
. 
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REVIEW OF LITERATURE 
 
Arteams (260 AD) had given many clinical descriptions of pulmonary disease of which 
'pneumodes' might be the same as chronic bronchitis, emphysema or bronchial asthma 
leading to congestive cardiac failure. 
In Europe, Bodham (1808) and Laennec (1827) made the classic description of chronic 
bronchitis & emphysema. 
Laennec in 1926 described the clinical and pathological characteristics of cause heart 
failure in otherwise healthy heart. 
In 1934 Kountz and Alexander who were studying emphysema stated that "it appears that 
heart is affected in majority of patients with emphysema". 
I.T.T. Higgins in 1959 had studied men between the ages of 25 and 64 to know the 
relationship between smoking and respiratory symptoms. A clear relationship between 
smoking and persistent cough and sputum production has been found.  
In 1959 The Medical Research Council in its publications used the term chronic 
bronchitis to define expectoration when other causes such as bronchiectasis or 
tuberculosis have been excluded, to patients who have coughed up sputum on most days 
during at least for 3 consecutive months in 2 successive years  
1963 Christer Larson studied 246 Swedish adults with severe α1 –antitrypsin deficiency; 
primary emphysema was present in 109cases.  
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By 1964, the Advisory Committee to the Surgeon General of the United States had 
concluded that cigarette smoking was a major risk factor for mortality from chronic 
bronchitis and emphysema. Subsequent longitudinal studies have shown accelerated 
decline in the volume of air exhaled within the first second of the forced expiratory 
maneuver (FEV1) in a dose-response relationship to the intensity of cigarette smoking, 
which is typically expressed as pack-years (average number of packs of cigarette smoked 
per day multiplied by total number of years of smoking)   
1975, Earliest nocturnal polygraph studies were done  
1977, Flick MR et al, did a land mark study is to show that Patients with COPD 
experienced a worsening of hypoxia. 
1964-1973 Boushy and colleagues published a series of papers on the subject of 
prognostic factors in COPD and the prognostic values of lung function tests 
1977 Boushy SF et al. described the results of hemodynamic changes in 136 patients with 
COPD including serial studies, correlating pulmonary function tests, arterial oxygen 
pressure, and arterial carbon dioxide tension with hemodynamic parameters. 
1983, Catterall TR et al., studied about transient hypoxemia during sleep in COPD 
patients. Long-term oxygen in conjunction with pulmonary rehabilitation, it also 
improves quality of life  
1991, Weitzen blume et.al. analysed the evaluation of physiological variables in patients 
with COPD before & during long term oxygen therapy. 
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DEFINITION 
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow 
limitation and a range of pathological changes in the lung, some significant extra 
pulmonary effects, and important comorbidities which may contribute to the severity of the 
disease in individual patients. Thus, COPD should be regarded as a pulmonary disease, but 
these significant comorbidities must be taken into account in a comprehensive diagnostic 
assessment of severity and in determining appropriate treatment.1,7,8 
Based on current knowledge, a working definition is: 
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease 
with some significant extra pulmonary effects that may contribute to the severity in 
individual patients. Its pulmonary component is characterized by airflow limitation that is 
not fully reversible. The airflow limitation is usually progressive and associated with an 
abnormal inflammatory response of the lung to noxious particles or gases.8 
Airflow Limitation in COPD 
The chronic airflow limitation characteristic of COPD is caused by a mixture of small 
airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the 
relative contributions of which vary from person to person. Chronic inflammation causes 
structural changes and narrowing of the small airways. Destruction of the lung 
parenchyma, also by inflammatory processes, leads 
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Figure.1  
INFLAMMATION IN COPD
AIRFLOW LIMITATION
Small airway disease
Airway destruction
Airway remodelling
Parenchymal destruction
Loss of alveolar attachments
Decrease of elastic recoil
 
to the loss of alveolar attachments to the small airways and decreases lung elastic recoil; in 
turn, these changes diminish the ability of the airways to remain open during expiration. 
Airflow limitation is best measured by Spirometry, as this is the most widely available, 
reproducible test of lung function Many previous definitions of COPD have emphasized 
the terms “emphysema” and “chronic bronchitis,” which are not included in the definition 
used in this and earlier GOLD reports. Emphysema, or destruction of the gas exchanging 
surfaces of the lung (alveoli), is a pathological term that is often (but incorrectly) used 
clinically and describes only one of several structural abnormalities present in patients with 
COPD. Chronic bronchitis, or the presence of cough and sputum production for at least 3 
months in each of two consecutive years, remains a clinically and epidemiologically useful 
term. However, it does not reflect the major impact of airflow limitation on morbidity and 
mortality in COPD patients. It is also important to recognize that cough and sputum 
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production may precede the development of airflow limitation; conversely, some patients 
develop significant airflow limitation without chronic cough and sputum production.1,8 
NATURAL HISTORY 
    COPD has a variable natural history and not all individuals follow the same       course. 
However, COPD is generally a progressive disease, especially if a patient's exposure to 
noxious agents continues. Stopping exposure to these agents, even when significant 
airflow limitation is present, may result in some improvement in lung function and slow 
or even halt the progression of the disease. However, once developed, COPD and its 
comorbidities cannot be cured and thus must be treated continuously. COPD treatment 
can reduce symptoms, improve quality of life, reduce exacerbations, and possibly reduce 
mortality1,8,12 
Spirometric Classification of Severity1,7,10 
For educational reasons, a simple spirometric classification of disease severity into four 
stages is recommended. Spirometry is essential for diagnosis and provides a useful 
description of the severity of pathological changes in COPD. Specific spirometric 
cutpoints (e.g., post bronchodilator FEV1/FVC ratio < 0.70 or FEV1 < 80, 50, or 30% 
predicted) are used for purposes of simplicity 
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Table. 1  GOLD CRITERIA OF COPD SEVERITY1,3,7,8 
GOLD 
Stage 
Severity Symptoms Spirometry 
0 At Risk Chronic cough, sputum 
production 
Normal 
I Mild With or without 
chronic cough or 
sputum production 
FEV1/FVC <0.7 and FEV1 >80% predicted 
  
IIA Moderate With or without 
chronic cough or 
sputum production 
FEV1/FVC <0.7 and 50% FEV1 <80% 
predicted 
  
III Severe With or without 
chronic cough or 
sputum production 
FEV1/FVC <0.7 and 30% FEV1 <50% 
predicted 
  
IV Very 
Severe 
With or without 
chronic cough or 
sputum production 
FEV1/FVC <0.7 and FEV1 <30%(OR) 
FEV1 <50% predicted with respiratory 
failure or signs of right heart failure 
 
 
RISK FACTORS 
For COPD has grown, so has the recognition that essentially all risk for COPD results 
from a gene environment interaction. Thus, of two people with the same smoking history, 
only one may develop COPD due to differences in genetic predisposition to the disease, 
or in how long they live. Risk factors for COPD may also be related in more complex 
ways. For example, gender may influence whether a person takes up smoking or 
experiences certain occupational or environmental exposures; socioeconomic status may 
be linked to a child's birth weight (as it impacts on lung growth and development); and 
longer life expectancy will allow greater lifetime exposure to risk factors. Understanding 
the relationships and interactions among risk factors requires further investigation1,7,8. 
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Figure. 2 
Risk Factors for COPD 
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Table.2     RISK FACTORS FOR COPD.8 
Genes Exposure to particles 
Tobacco smoke 
Occupational dusts, organic and inorganic 
Indoor air pollution from heating and cooking with biomass in poorly vented dwellings 
Outdoor air pollution 
Lung Growth and Development  
Oxidative stress Gender 
Age  
Respiratory infections  
Previous tuberculosis  
Socioeconomic status  
Nutrition 
Comorbidities 
Tobacco smoke 
Tobacco smoke, which is a mixture of over 4000 chemical constituents, is the most 
important cause. Amongst males, tobacco smoking is responsible for more than 80% of 
patients. Both cigarette and ‘bidi’ smoking are equally responsible Pipe and ‘hookah’ 
smoking are also important in causing COPD. There is no reliable information on 
smoking associated COPD in women in whom the overall prevalence of smoking is very 
low. Besides active tobacco smoking, exposure to smoking from others i.e. passive 
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smoking, better termed as Environmental Tobacco Smoke (ETS) exposure, may also play 
a contributory role especially in nonsmoker individuals including women1,2,7,9 
Solid fuel combustion 
The smoke from combustion of solid fuels such as dried dung, wood and crop residue 
used for cooking and heating, especially in villages, semi urban and slum areas, is an 
important cause of pollution of the indoor air. It is responsible for a large number of 
COPD in the rural inhabitants in general and women in particularly2,9 
Air pollution 
Exhausts from vehicles and industrial units; dusts, fumes and smoke from burning of crop 
residues in the field constitute important sources of air pollution. Chronic exposure to 
polluted air is an important cause of chronic respiratory diseases such as the COPD1,3,8 
Gender 
The role of gender in determining COPD risk remains unclear. In the past, most studies 
showed that COPD prevalence and mortality were greater among men than women. 
Studies from developed countries show that the prevalence of the disease is now almost 
equal in men and women, which probably reflects changing patterns of tobacco 
smoking.7,13  
 
 
 13 
 
Respiratory Infections 
Respiratory infections (viral and bacterial) may contribute to the pathogenesis and 
progression of COPD, and the bacterial colonization associated with airway 
inflammation, and may also play a significant role in exacerbations. A history of severe 
childhood respiratory infection has been associated with reduced lung function and 
increased respiratory symptoms in adulthood. . HIV infection has been shown to 
accelerate the onset of smoking-related emphysema; HIV induced pulmonary 
inflammation may play a role in this process. A history of tuberculosis has been found to 
be associated with airflow obstruction in adults older than 40 years.1,8 
 
Asthma 
Asthma may be risk factor for the development of COPD, although the evidence  
is not conclusive. In a report from a longitudinal cohort of the Tucson Epidemiological 
Study of Airway Obstructive Disease adults with asthma were found to have a twelve-
fold higher risk of acquiring COPD over time than those without asthma, after adjusting 
for smoking1,13 
 
PATHOGENESIS 
Pathological changes characteristic of COPD are found in the proximal airways, 
peripheral airways, lung parenchyma, and pulmonary vasculature. These changes 
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                                Figure.3   ASTHMA AND COPD8 
         
include chronic inflammation, and structural changes resulting from repeated injury and 
repair.61 
 • Inhaled cigarette smoke and other noxious particles cause lung inflammation, a normal 
response which appears to be amplified in patients who develop COPD 
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.• There is a characteristic pattern of inflammation in the lungs of COPD patients, with 
increased numbers of neutrophils (in the airway lumen), macrophages 
LUNG INFLAMMATION
COPD PATHOLOGY
Oxidative
stress Proteinases
Repair 
mechanisms
Anti-proteinasesAnti-oxidants
Host factors
Amplifying mechanisms
Cigarette smoke
Biomass particles
Particulates
  
                          Figure. 4  PATHOLOGY OF COPD 
(Airway lumen, airway wall, and parenchyma), and CD8+ lymphocytes (airway wall and 
parenchyma). The pattern is different from that seen in asthma.1 
• Lung inflammation is further amplified by oxidative stress and an excess of proteases in 
the lung Physiological changes characteristic of the disease include mucus 
hypersecretion, airflow limitation and air trapping (leading to hyperinflation), gas 
exchange abnormalities, and cor pulmonale.  
Exacerbations represent a further amplification of the inflammatory response in the 
airways of patients with COPD, and may be triggered by infection with bacteria or 
viruses or by environmental pollutants.6 
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Table 3     PATHOLOGICAL CHANGES COPD8,61 
 
Proximal airways (trachea, bronchi > 2 mm internal diameter) 
Goblet cells hyperplasia, enlarged submucosal glands (both 
leading to mucus hypersecretion), squamous metaplasia of epithelium 
 
Peripheral airways (bronchioles < 2mm i.d.) 
Airway wall thickening, peribronchial fibrosis, luminal inflammatory exudate, 
airway narrowing (obstructive bronchiolitis) Increased inflammatory response and 
exudate correlated with disease severity 
 
Lung parenchyma (respiratory bronchioles and alveoli) 
Destruction of gas exchange air spaces- the respiratory bronchioles, alveolar ducts 
and alveoli. 
*Centrilobular emphysema: dilatation and destruction of respiratory bronchioles; 
most commonly seen in smokers 
 
 *Panacinar emphysema: destruction of alveolar sacs as well as respiratory 
bronchioles; most commonly seen in alpha-1 antitrypsin deficiency 
 
Pulmonary vasculature 
Thickening of intima, endothelial cell dysfunction, smooth muscle pulmonary 
hypertension 
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Figure. 5   PATHOGENESIS OF COPD8 
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Table 46 
Differences in Pulmonary Inflammation Between Asthma and COPD 
 
 
 
COPD Asthma Severe 
Asthma 
Cells Neutrophils ++ 
Macrophages +++ 
CD8+ T cells (Tc1) 
Eosinophils ++ 
Macrophages + 
CD4+ T cells (Th2) 
Neutrophils + 
Macrophages 
CD4+ T cells 
(Th2), CD8+ 
T cells (Tc1) 
Key 
mediators 
IL-8 
TNF-_, IL-1_, IL-6 
No+ 
Eotaxin 
IL-4, IL-5, IL-13 
NO +++ 
IL-8 
IL-5, IL-13 
NO ++ 
 
Oxidative 
stress 
+++ + +++ 
Site of disease Peripheral airways 
Lung parenchyma 
Pulmonary vessels 
Proximal airways Proximal 
airways 
Peripheral 
airways 
Consequences Squamous metaplasia 
Mucous metaplasia 
Small airway fibrosis 
Parenchymal destruction 
Pulmonary vascular 
remodeling 
Fragile epithelium 
Mucous metaplasia 
Basement membrane 
Bronchoconstriction 
 
Response to 
therapy 
Small broncho dilatation 
response 
Poor response to steroids 
Large broncho 
dilatation  response 
Good response to 
steroids 
Smaller 
broncho 
dilatation  
response 
Reduced 
response to 
steroids 
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Pulmonary Hypertension 
Mild to moderate pulmonary hypertension may develop late in the course of COPD and is 
due to hypoxic vasoconstriction of small pulmonary arteries, eventually resulting in 
structural changes that include intimal hyperplasia and later smooth muscle hypertrophy/ 
hyperplasia62 
Chronic hypoxia
Pulmonary vasoconstriction
Muscularization
Intimal 
hyperplasia
Fibrosis
Obliteration
Pulmonary hypertension
Cor pulmonale
Death
Edema
Pulmonary Hypertension in COPD
Figure. 6 COPD AND PULMONARY HYPERTENSION 
Systemic Features of COPD6,8 
• Cachexia: loss of fat free mass 
• Skeletal muscle wasting: apoptosis, disuse atrophy 
• Osteoporosis 
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• Depression 
• Normochromic, normocytic anemia 
• Increased risk of cardiovascular disease: associated with CRP 
MANAGEMENT 
Management of Mild to Moderate COPD (Stages I and II) involves the avoidance of risk 
factors to prevent disease progression and pharmacotherapy as needed to control 
symptoms. Severe (Stage III) and Very Severe (Stage IV) COPD often require the 
integration of several different disciplines, a variety of treatment approaches, and a 
commitment of the clinician to the continued support of the patient as the illness 
progresses1,3,6. In addition to patient education, health advice, and pharmacotherapy, 
COPD patients may require specific counseling about smoking cessation, instruction in 
physical exercise, nutritional advice, and continued nursing support. Not all approaches 
are needed for every patient, and assessing the potential benefit of each approach at each 
stage of the illness is a crucial aspect of effective disease management. While disease 
prevention is the ultimate goal, once COPD has been diagnosed, effective management 
should be aimed at the following goals8:  
• Relieve symptoms 
• Prevent disease progression 
• Improve exercise tolerance 
• Improve health status 
• Prevent and treat complications 
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• Prevent and treat exacerbations 
• Reduce mortality 
A clinical diagnosis of COPD should be considered in any patient who has dyspnoea, 
chronic cough or sputum production, and/or a history of exposure to risk factors for the 
disease. The diagnosis should be confirmed by spirometry. For the diagnosis and 
assessment of COPD, spirometry is the gold standard as it is the most reproducible, 
standardized, and objective way of measuring airflow limitation. The presence of a post 
bronchodilator FEV1/FVC < 0.70 confirms the presence of airflow limitation that is not 
fully reversible1.8. Measurement of arterial blood gas tensions should be considered in all 
patients with FEV1 < 50% predicted or clinical signs suggestive of respiratory failure or 
right heart failure4.  
(1) Assess and Monitor Disease;   
(2) Reduce Risk Factors;  
(3) Manage Stable COPD; and  
(4) Manage Exacerbations. 
 
Dyspnoea. Dyspnoea, the hallmark symptom of COPD, is the reason most patients seek 
medical attention and is a major cause of disability and anxiety associated with the 
disease. Typical COPD patients describe their dyspnoea as a sense of increased effort to 
breathe, heaviness, air hunger, or gasping5,6.  It is often possible to distinguish the 
breathlessness of COPD from that due to other causes by analysis of the terms used, 
although there is considerable overlap with descriptors of bronchial asthma.  Initially, 
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breathlessness is only noted on unusual effort (e.g., walking or running up a flight of 
stairs) and may be avoided entirely by appropriate behavioral change. As lung function 
deteriorates, breathlessness becomes more intrusive, and patients may notice that they are 
unable to walk at the same speed as other people of the same age or carry out activities.  
Eventually, breathlessness is present during everyday activities (e.g., dressing, washing) 
or at rest2 
Cough. Chronic cough, often the first symptom of COPD to develop, is often discounted 
by the patient as an expected consequence of smoking and/or environmental exposures. 
Initially, the cough may be intermittent, but later is present every day, often throughout 
the day. The chronic cough in COPD may be unproductive. In some cases, significant 
airflow limitation may develop without the presence of a cough1,4,6.  
Sputum production. COPD patients commonly raise small quantities of tenacious 
sputum after coughing bouts. Regular production of sputum for 3 or more months in 2 
consecutive years (in the absence of any other conditions that may explain it) is the 
epidemiological definition of chronic bronchitis, but this is a somewhat arbitrary 
definition that does not reflect the range of sputum production in COPD patients. Sputum 
production is often difficult to evaluate because patients may swallow sputum rather than 
expectorate it, a habit subject to significant cultural and gender variation. Patients 
producing large volumes of sputum may have the underlying bronchiectasis. The 
presence of purulent sputum reflects an increase in inflammatory mediators, and its 
development may identify the onset of an exacerbation5,61 
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Wheezing and chest tightness. Wheezing and chest tightness are nonspecific symptoms 
that may vary between days, and over the course of a single day. These symptoms may be 
present in Stage I: Mild COPD, but are more characteristic of asthma or Stage III: Severe 
COPD and Stage IV: Very Severe COPD. Audible wheeze may arise at a laryngeal level 
and need not be accompanied by auscultatory abnormalities. Alternatively, widespread 
inspiratory or expiratory wheezes can be present on listening to the chest. Chest tightness 
often follows exertion, is poorly localized, is muscular in character, and may arise from 
isometric contraction of the intercostals muscles. An absence of wheezing or chest 
tightness does not exclude a diagnosis of COPD, nor does their presence confirm a 
diagnosis of asthma.8 
Medical History 
A detailed medical history of a new patient known or thought to have COPD should 
assess the patient’s exposure to risk factors, such as smoking and occupational or 
environmental exposures Past medical history, including asthma, allergy, sinusitis, or 
nasal polyps, respiratory infections in childhood; other respiratory diseases. Family 
history of COPD or other chronic respiratory disease.  Pattern of symptom development: 
COPD typically develops in adult life and most patients are conscious of increased 
breathlessness, more frequent winter colds, and some social restriction for a number of 
years before seeking medical help.  
• History of exacerbations or previous hospitalizations for respiratory disorder: Patients 
may be aware of periodic worsening of symptoms even if these episodes have not been 
identified as exacerbations of COPD.  
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• Presence of comorbidities, such as heart disease, malignancies, osteoporosis, and 
musculoskeletal disorders, which may also contribute to restriction of activity. 
•Appropriateness of current medical treatments: For example, betablockers commonly 
prescribed for heart disease are usually contraindicated in COPD.  
• Possibilities for reducing risk factors, especially smoking cessation 
Physical Examination 
 Though an important part of patient care, physical examination is rarely diagnostic in 
COPD.  Detection has a relatively low sensitivity and specificity. A number of physical 
signs may be present in COPD, but their absence does not exclude the diagnosis.  
• Central cyanosis, or bluish discoloration of the mucosal membranes, 
• Common chest wall abnormalities, which reflect the pulmonary hyperinflation seen in 
COPD, include relatively horizontal ribs, “barrel-shaped” chest, and protruding abdomen.  
• Flattening of the hemidiaphragms may be associated with paradoxical indrawing of the 
lower rib cage on inspiration, and widening of the xiphisternal angle.  
• Resting respiratory rate is often increased COPD patients often have resting muscle 
activation while lying supine. Use of the scalene and sternocleidomastoid muscles is a 
further indicator of respiratory distress.  
• Ankle or lower leg edema can be a sign of right heart failure. . Patients with COPD 
often have reduced breath sounds, but this finding is not sufficiently characteristic to 
make the diagnosis5. 
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• The presence of wheezing during quiet breathing is a useful pointer to airflow 
limitation. However, wheezing heard only after forced expiration has not been validated 
as a diagnostic test for COPD.1 
• Inspiratory crackles occur in some COPD patients but are of little help diagnostically.6 
Measurement of Airflow Limitation (Spirometry)2,8 
Spirometry should be undertaken in all patients who may have COPD. It is needed to 
make a confident diagnosis of COPD and to exclude other diagnoses that may present 
with similar symptoms. It is the best standardized, most reproducible, and most objective 
measurement of airflow limitation available. Good quality spirometric measurement is 
possible and all health care workers who care for COPD patients should have access to 
spirometry.8,10   
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CLASSIFICATION OF OBSTRUCTIVE OR RESTRICTIVE OR MIXED AIRWAY 
DISEASE BASED ON FVC AND FEV1 VALUES10 
 
Spirometry should measure the volume of air forcibly exhaled from the point of maximal 
inspiration (forced vital capacity, FVC) and the volume of air exhaled during the first 
second of this maneuver (forced expiratory volume in one second, FEV1)10, and the ratio 
of these two measurements (FEV1/FVC) should be calculated.  Spirometry 
measurements are evaluated by comparison with reference values based on age, height, 
sex, and race8,10  
 
 
 
 
FEV1/FVC 
 27 
 
Performance 
• Spirometry should be performed using techniques that meet published standards. 
• The expiratory volume/time traces should be smooth and free from irregularities. • The 
recording should go on long enough for a volume plateau to be reached, which may take 
more than 15 seconds in severe disease8,10,18.  
• Both FVC and FEV1 should be the largest value obtained from any of 3 technically 
satisfactory curves and the FVC and FEV1 values in these three curves should vary by no 
more than 5% or 100 ml, whichever is greater23. 
• The FEV1/FVC ratio should be taken from the technically acceptable curve with the 
largest sum of FVC and FEV1. 
 
 
Evaluation 
• Spirometry measurements are evaluated by comparison of the results with appropriate 
reference values based on age, height, sex, and race 10  
• The presence of a post bronchodilator FEV1/FVC<0.70 confirms the presence of 
airflow limitation that is not fully reversible18,23 
 
Chest X-ray. An abnormal chest X-ray is seldom diagnostic in COPD unless obvious 
bullous disease is present, but it is valuable in excluding alternative diagnoses and 
establishing the presence of significant comorbidities such as cardiac failure. 
Radiological changes associated with COPD include signs of hyperinflation (flattened 
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diaphragm on the lateral chest film, and an increase in the volume of the retrosternal air 
space), hyperlucency of the lungs, and rapid tapering of the vascular markings. Computed 
tomography (CT) of the chest is not routinely recommended. However, when there is 
doubt about the diagnosis of COPD, high resolution CT (HRCT) scanning might help in 
the differential diagnosis.4,6  
 
Arterial blood gas measurement. In advanced COPD, measurement of arterial blood 
gases is important. This test should be performed in the stable patients with FEV1 < 50% 
predicted or with clinical signs suggestive of respiratory failure or right heart failure. 
Several considerations are important to ensure accurate test results. 66  
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Table 5.    EMPHYSEMA VS CHRONIC BRONCHITIS4 
  Type A: Pink Puffer (Emphysema 
Predominant) 
Type B: Blue Bloater (Bronchitis 
Predominant) 
History and 
physical 
examination 
Major complaint is dyspnoea, often 
severe, usually presenting after age 
50. Cough is rare, with scant clear, 
mucoid sputum. Patients are thin, 
with recent weight loss common. 
They appear uncomfortable, with 
evident use of accessory muscles of 
respiration. Chest is very quiet 
without adventitious sounds. No 
peripheral edema. 
Major complaint is chronic cough, 
productive of mucopurulent sputum, 
with frequent exacerbations due to 
chest infections. Often presents in 
late 30s and 40s. Dyspnoea usually 
mild, but may note limitations to 
exercise. Chest is noisy, with 
rhonchi invariably present; wheezes 
are common. 
Laboratory studies Hemoglobin usually normal. PaO2 
normal to slightly reduced but SaO2 
normal at rest. PaCO2 normal to 
slightly reduced. Chest radiograph 
shows hyperinflation with flattened 
diaphragms. Vascular markings are 
diminished, particularly at the apices. 
  
Hemoglobin usually elevated. PaO2 
reduced and PaCO2 slightly to 
markedly elevated. Chest 
radiograph shows increased 
interstitial markings ("dirty lungs"), 
especially at bases. Diaphragms are 
not flattened. 
  
Pulmonary function 
tests 
Airflow obstruction ubiquitous. Total 
lung capacity increased, sometimes 
markedly so. DLCO reduced. Static 
lung compliance increased. 
  
Airflow obstruction ubiquitous. 
Total lung capacity generally 
normal but may be slightly 
increased. DLCO normal. Static lung 
compliance normal. 
  
Special evaluations  
  V/Q matching Increased ventilation to high areas, 
i.e., high dead space ventilation. 
Increased perfusion to low areas.  
  Hemodynamics Cardiac output normal to slightly low. 
Pulmonary artery pressures mildly 
elevated and increase with exercise. 
Cardiac output normal. Pulmonary 
artery pressures elevated, 
sometimes markedly so, and 
worsen with exercise. 
  Nocturnal 
ventilation 
Mild to moderate degree of oxygen 
desaturation not usually associated 
with obstructive sleep apnea. 
Severe oxygen desaturation, 
frequently associated with 
obstructive sleep apnea.  
  Exercise 
ventilation 
Increased minute ventilation for level 
of oxygen consumption. PaO2 tends to 
fall, PaCO2 rises slightly 
Decreased minute ventilation for 
level of oxygen consumption. PaO2 
may rise; PaCO2 may rise  
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Monitor Disease Progression and Development of 
Complications 
COPD is usually a progressive disease. Lung function can be expected to worsen over 
time. As at the initial assessment, follow-up visits should include a physical examination 
and discussion of symptoms, particularly any new or worsening symptoms8. 
Pulmonary function. A patient’s decline in lung function is best tracked by periodic 
spirometry measurements although useful information about lung function decline is 
unlikely from spirometry measurements performed more than once a year10 
Electrocardiography findings 
ECG may show sinus tachycardia. In advanced disease, chronic pulmonary hypertension 
may produce electrocardiographic abnormalities typical of cor pulmonale 
.Supraventricular arrhythmias (multifocal atrial tachycardia, atrial flutter, and atrial 
fibrillation) and ventricular irritability also occur69 
Diagnosis of right heart failure or cor pulmonale. 
Elevation of the jugular venous pressure and the presence of pitting ankle edema are 
often the most useful findings suggestive of cor pulmonale in clinical practice.  Firm 
diagnosis of cor pulmonale can be made through a number of investigations, including 
radiography, electrocardiography, echocardiography67,69 
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Hematocrit. Polycythemia can develop in the presence of arterial hypoxemia, especially 
in continuing smokers43, and can be identified by Hematocrit > 55%. Anemia is more 
prevalent than previously thought, affecting almost a quarter of COPD patients in one 
hospital series. A low Hematocrit indicates a poor prognosis in COPD patients receiving 
long-term oxygen treatment1,7. 
 
 
Monitor Pharmacotherapy and Other Medical Treatment 
In order to adjust therapy appropriately as the disease progresses, each follow-up visit 
should include a discussion of the current therapeutic regimen. Dosages of various 
medications, adherence to the regimen, inhaler technique, effectiveness of the current 
regime at controlling symptoms, and side effects of treatment should be monitored8,10. 
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Monitor Exacerbation History 
During periodic assessments, should question the patient and evaluate any records of 
exacerbations, both self treated and those treated by other health care providers. 
Frequency, severity, and likely causes of exacerbations should be evaluated. Frequency, 
severity, likely causes of exacerbations. Increased sputum volume, acutely worsening 
dysponea, and the presence of purulent sputum should be noted.  Severity can be 
estimated by the increased need for bronchodilator medication or glucocorticosteroids 
and by the need for antibiotic treatment1,4,8 
Figure.7
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Monitor Comorbidities 
Comorbidities are common in COPD. Some may be an indirect result of COPD, arising 
independently but more likely to occur when COPD is present, e.g., ischemic heart 
disease, bronchial carcinoma, osteoporosis, and depression.. Other comorbid conditions 
may coexist with COPD because they become prevalent as part of the aging process, e.g., 
arthritis, diabetes, reflux esophagitis and depression Reduction of total personal exposure 
to tobacco smoke, occupational dusts and chemicals, and indoor and outdoor air 
pollutants are important goals to prevent the onset and progression of COPD8. 
• Smoking cessation is the single most effective and cost effective intervention in most 
people to reduce the risk of developing COPD and stop its progression strategies aimed at 
reducing the burden of inhaled particles and gases40. 
• Reducing the risk from indoor and outdoor air pollution is feasible and requires a 
combination of public policy and protective steps taken by individual patients1,8. 
 
Smoking Prevention 
Comprehensive tobacco control policies and programs with clear, consistent, and 
repeated nonsmoking messages should be delivered through every feasible channel, 
including health care providers, community activities, schools, and radio, television, and 
print media. National and local campaigns should be undertaken to reduce exposure to 
tobacco smoke in public forums. Such bans are proving to be workable and to result in 
measurable gains in respiratory health. Legislation to 
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establish smoke free schools, public facilities, and work environments should be 
developed and implemented by government officials and public health workers, and 
encouraged by the public. Smoking prevention programs should target all ages, including 
young children, adolescents, young adults, and pregnant women. Interventions to prevent 
smoking uptake and maximize cessation should be implemented at every level of the 
health care system. Physicians and public health officials should encourage smoke free 
homes. The first exposure to cigarette smoke may begin in utero when the fetus is 
exposed to bloodborne metabolites from the mother. Education to reduce in utero risks 
for unborn children is also of great importance to prevent the effects of maternal smoking 
in reducing lung growth and causing airways disease in early and later life8. 
BRIEF STRATEGIES TO HELP THE PATIENT WILLING TO QUIT 
SMOKING8 
• ASK              Systematically identify all tobacco users at every visit. 
• ADVISE Strongly urge all tobacco users to quit. 
• ASSESS  Determine willingness to make a quit attempt 
• ASSIST Aid the patient in quitting 
• ARRANGE   Schedule follow-up contact 
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PHARMACOLOGICAL TREATMENT 
Bronchodilators 
Medications that increase the FEV1 or change other spirometric variables, usually by 
altering airway smooth muscle tone, are termed bronchodilators, since the improvements 
in expiratory flow reflect widening of the airways rather than changes in lung elastic 
recoil. Such drugs improve emptying of the lungs, tend to reduce dynamic hyperinflation 
at rest and during exercise, and improve exercise performance 1,3. 
β2-agonists. The principal action of β2-agonists is t. relax airway smooth muscle by 
stimulating β2-adrenergic receptors, which increases cyclic AMP and produces functional 
antagonism to bronchoconstriction. Oral therapy is slower in onset and has more side 
effects than inhaled treatment 
Short-acting 
Fenoterol, Levalbuterol, Salbutamol, Terbutaline  
Long-acting 
Formoterol ,Arformoterol, Indacaterol8 ,Salmeterol 
 
Anticholinergics. The most important effect of anticholinergic medications, such as 
ipratropium, oxitropium and tiotropium bromide, in COPD patients appears to be 
blockage of acetylcholine’s effect on M3 receptors. Current short-acting drugs also block 
M2 receptors and modify transmission at the pre-ganglionic junction, although these 
effects appear less important in COPD. The long-acting anticholinergic tiotropium has a 
 36 
 
pharmacokinetic selectivity for the M3 and M1 receptors. The bronchodilating effect of 
short-acting inhaled anticholinergics lasts longer than that of short-acting β2-agonists 1,8 
Short-acting 
Ipratropium bromide ,Oxitropium bromide 
Long-acting 
Tiotropium 
Combination short-acting β2-agonists plus anticholinergic in one inhaler 
Fenoterol/Ipratropium  
Salbutamol/Ipratropium 
Methylxanthines. Controversy remains about the exact effects of xanthine derivatives. 
They may act as nonselective phosphodiesterase inhibitors, but have also been reported to 
have a range of no bronchodilator actions, the significance of which is disputed 
Aminophylline, Theophylline  
Glucocorticosteroids 
The effects of oral and inhaled glucocorticosteroids in COPD are much less dramatic than 
in asthma, and their role in the management of stable COPD is limited to specific 
indications  
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Inhaled glucocorticosteroids.  
Most studies have shown that regular treatment with inhaled glucocorticosteroids does 
not modify the long-term decline of FEV1 in patients with COPD  
Beclomethasone  
Budesonide  
Fluticasone propionate 
Combination inhaled glucocorticosteroid/bronchodilator therapy:  
An inhaled glucocorticosteroid combined with a long-acting β2-agonist is more effective 
than the individual components in reducing exacerbations and improving lung function 
and health status 
Formoterol/Budesonide  
Salmeterol/Fluticasone propionate 
Oral glucocorticosteroids:  
short-term. Many existing COPD guidelines recommend the use of a short course (two 
weeks) of oral glucocorticosteroids to identify COPD patients who might benefit from 
long-term treatment with oral or inhaled glucocorticosteroids. 
Prednisone  
Methyl-prednisolone 
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Table. 6 
IV: Very SevereIII: SevereII: ModerateI: Mild
Therapy at Each Stage of COPD
 FEV1/FVC < 70% 
 FEV1 > 80% 
predicted
 FEV1/FVC < 70%
 50% < FEV1 < 80%
predicted
 FEV1/FVC < 70%
 30% < FEV1 < 
50% predicted
 FEV1/FVC < 70% 
 FEV1 < 30% 
predicted
or FEV1 < 50% 
predicted plus 
chronic respiratory 
failure
Add regular treatment with one or more long-acting 
bronchodilators (when needed);  Add rehabilitation
Add inhaled glucocorticosteroids if 
repeated exacerbations
Active reduction of risk factor(s); influenza vaccination
Add short-acting bronchodilator (when needed)
Add long term 
oxygen if chronic  
respiratory failure.  
Consider surgical 
treatments
 
VACCINES 
Influenza vaccines can reduce serious illness and death in COPD patients by about 50% 
Rehabilitation:  
All COPD patients benefit from exercise training programs, improving with respect to 
both exercise tolerance and symptoms of dyspnoea and fatigue. 
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Mucolytic (mucokinetic, mucoregulator) agents 
(ambroxol, erdosteine, carbocysteine, iodinated glycerol). The regular use of mucolytics 
in COPD has been evaluated in a number of long-term studies with controversial results. 
Although a few patients with viscous sputum may benefit from mucolytics 
Oxygen Therapy 
Oxygen therapy, one of the principal nonpharmacologic treatments for patients with 
Stage IV: Very Severe COPD, can be administered in three ways: long-term continuous 
therapy, during exercise, and to relieve acute dyspnoea. The primary goal of oxygen 
therapy is to increase the baseline PaO2 to at least 8.0 kPa (60 mm Hg) at sea level and 
rest, and/or produce an SaO2 at least 90%, which will preserve vital organ function by 
ensuring adequate delivery of oxygen1,6,8 
 
Surgical Treatments 
Bullectomy. Bullectomy is an older surgical procedure for bullous emphysema. Removal 
of a large bulla that does not contribute to gas exchange decompresses the adjacent lung 
parenchyma. Bullectomy can be performed thoracoscopically. In carefully selected 
patients, this procedure is effective in reducing dyspnoea and improving lung function3,8 
Lung transplantation. In appropriately selected patients with very advanced COPD, lung 
transplantation has been shown to improve quality of life and functional capacity. Criteria 
for referral for lung transplantation include FEV1 < 35% predicted, PaO2 <7.38.0 kPa 
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(5560 mm Hg), PaCO2 > 6.7 kPa (50 mm Hg), and secondary pulmonary hypertension 
1,3,8
 
 
MANAGE EXACERBATIONS 
The most common causes of an exacerbation are infection of the tracheobronchial tree 
and air pollution, but the cause of about one third of severe exacerbations cannot be 
identified.  
• Inhaled bronchodilators (particularly inhaled β2-agonists with or without 
anticholinergics) and oral glucocorticosteroids are effective treatments for exacerbations 
of COPD. 
• Patients experiencing COPD exacerbations with clinical signs of airway infection (e.g., 
increased sputum purulence) may benefit from antibiotic treatment.  
• Noninvasive mechanical ventilation in  exacerbations improves respiratory acidosis, 
increases pH, decreases the need for endotracheal intubation, and reduces PaCO2, 
respiratory rate, severity of breathlessness, the length of hospital stay, and mortality  
• Medications and education to help prevent future exacerbations should be considered as 
part of follow-up, as exacerbations affect the quality of life and prognosis of patients with 
COPD 
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MATERIALS AND METHODS 
SETTING 
The study was conducted in Annal Gandhi Memorial Government Hospital, Trichy which 
is attached to K. A. P. Viswanatham Government Medical College, Trichy. 
DESIGN OF STUDY 
It was an observational type of study. Interview technique was used to collect information 
on a predesigned proforma. 
PERIOD OF STUDY 
It was conducted in a time period from January 2011 to October 2011. 
SAMPLE SIZE 
Hundred cases of Chronic Obstructive Pulmonary Disease. 
SELECTION OF STUDY SUBJECTS 
COPD patients above 40 years of age, admitted in medical wards with the diagnosis of 
Chronic Obstructive Pulmonary Disease. 
 
INCLUSION CRITERIA  
Adult males and females admitted in the medical wards with symptoms suggestive of 
airway obstruction of more than 2 years duration and in who clinical diagnosis of chronic 
obstructive pulmonary disease was made were included in the study. 
All these patients were subjected to clinical examination, ECG, chest X-ray, pulmonary 
function testing, pulse oximetry and Hematocrit analysis 
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On spirometry the presence of COPD was diagnosed by post bronchodilator values of 
(I) Forced expiratory volume in first second / Forced vital capacity (FEV1/FVC) less than 
70%. 
All patients were clinically stable at the time of conducting pulmonary function test. 
 
EXCLUSION CRITERIA 
Cases which excluded from the study were patients with primary diagnosis of bronchial 
asthma, pulmonary tuberculosis, Bronchiectasis, cases of sleep apnoea syndromes and 
patients with post infarction failure. 
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OBSERVATIONS AND RESULTS 
100 cases of COPD were studied; the results are tabulated as follows: 
Table.7   AGE WISE DISTRIBUTION 
AGE  MALE % FEMALE % TOTAL % 
41-50 8 8.6 0  8 8 
51-60 22 24 4 50 26 26 
61-70 46 50 0  46 46 
71-80 16 17.4 2 25 18 18 
81-90 0 0 2 25 2 2 
TOTAL 92 100 8 100 100 100 
 
From the above table it can be observed that the maximum case among males were 
between 61-70 years of age constituting 50% and the Minimum number cases were in the 
age group of 81-90 years being 0%. Among females, number of cases in 51-60 years was 
4 constituting 50% and in the age group of 71-80 and 81-90 were 2 cases each 
constituting of 25% each respectively. Both sexes put together the maximum cases were 
in age group of 61-70 years constitutes  46 % and minimum in the age group of 81-90 
years constituting only 2%.  
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CHART SHOWING AGE DISTRIBUTION IN THE STUDIED 
POPULATION 
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Table 8. SEX DISTRIBUTION IN STUDIED POPULATION 
 
SEX NO OF CASES PERCENTAGE 
MALE 92 92 
FEMALE 8 8 
TOTAL 100 100 
 
PIE CHART SHOWING SEX DISTRIBUTION 
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Table 9.  OCCUPATION OF THE PATIENTS 
 
Occupation No of cases percentage 
Agriculture 20 20 
Business 20 20 
Non-agricultural coolie 52 52 
House wife 8 8 
 
 
 
 
 
In the present study group majority of the patients were non- agricultural coolies  
accounting for 54%. The remaining were businessmen and agriculture 20% each. House 
wives were accounting for 8%. 
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Table 10.  RURAL- URBAN DISTRIBUTION  
 Cases Percentage 
RURAL 38 38 
URBAN 62 62 
TOTAL 100 100 
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Table.11.   DURATION OF ILLNESS 
DURATION IN 
YRS 
MALE FEMALE TOTAL PERCENT 
2-5 44 0 44 44 
6-10 34 2 36 36 
11-15 12 6 18 18 
16-20 2 0 4 4 
 
Majority of people in the present study group belonged to more than 2-5 years duration of 
illness. 
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Table 12.  RISK FACTOR EXPOSURE 
 
RISK FACTOR MALE FEMALE TOTAL PERCENTAGE 
CIGARETTE 
SMOKE 
86 0 86 86 
OCCUPATIONAL  2 0 2 2 
BURNT FUEL 4 8 12 12 
 
 
 
 
All the male patients were smokers; in female H/o exposure to smoke of burnt fuels was 
present in all case.  
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Table 13.  DURATION OF SMOKING HABITS 
 
PACK YEARS NO OF PATIENTS PERCENTAGE 
10-19 8 9.3 
20-29 26 30.2 
30-39 36 41.9 
>40 16 18.6 
TOTAL 86 100 
 
 
 
 
Most of the patients had more than 20 years and majority were in 
30-50 pack year exposure duration. 
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Table-14:   PRESENTING SYMPTOMS 
 
SYMPTOM NO OF PATIENTS PERCENTAGE 
COUGH 100 100 
EXPECTORATION 96 96 
DYSPNOEA 100 100 
WHEEZE 62 62 
FEVER 12 12 
 
 
All the patients presented with cough and dyspnoea. Expectoration and wheezing was 
present in majority of the patients and fever was present among a small percentage (12%) 
of patients. Majority of patients were in the stable state. 
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Table-15:   RESPIRATORY SIGNS 
SIGN NO OF PATIENTS PERCENTAGE 
REDUCED CHEST 
MOVEMENTS 
42 42 
CREPITATIONS/ 
RHONCHI 
84 84 
BARREL SHAPE 
CHEST 
46 46 
 
 
 
Most of patients presented with obesity, short neck and Nicotine stain in lips. 
 
 
 
0 20 40 60 80 100
REDUCED CHEST MOVEMENTS
CREPITATIONS/ RHONCHI
BARREL SHAPE CHEST
42
84
46
 53 
 
Table-16:    CHEST X RAY FINDINGS 
X-RAY FINDINGS NO OF CASES PERCENTAGE 
CHRONIC BRONCHITIS 32 32 
EMPHYSEMA 28 28 
CHRONIC 
BRONCHITIS+EMPHYSEMA 
18 18 
NORMAL 22 22 
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Table-17:   ECG FINDINGS 
FINDINGS IN ECG No of cases % 
LOW VOLTAGE COMPLEXES 24 24 
SINUS TACHYCARDIA 30 30 
L 1 SIGN 4 4 
RIGHT ATRIAL ENLARGEMENT 8 8 
RIGHT VENTRICLE ENLARGEMENT 2 2 
RIGHT BUNDLE BRANCH BLOCK 2 2 
NON PROGRESSION OF R WAVE IN VI-V3  26 26 
PERSISTANT OF S WAVE IN V5-V6 18 18 
NORMAL FINDINGS 26 26 
 
In this study, 26 patients, i.e. 26% of patients have normal findings. 30 cases (30%) have 
sinus tachycardia. Non progression R wave in V1-V3 accounts for 26% i.e. 26 cases. 
Persistent of S wave in V5-V5 accounts for 18%, Low voltage complex account for 24%, 
Lead 1 sign is just 4% of cases. 
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Table-18:   HEMOGLOBIN VALUES IN STUDIED POPULATION 
 
Hb in g% male % female % total % 
<10 14 15 2 25 16 16 
10 to11.9 36 39 6 75 42 42 
12 to 14.9 42 46 0 0 42 42 
>15 0 0 0 0 0 0 
TOTAL 92 100 8 100 100 100 
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Table -19:  HEMATOCRIT VALUES IN STUDIED PATIENTS 
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Table-20: PULSE OXIMETRY 
SaO2 No of patients Percentage 
<89 20 20 
89-92 62 62 
92-95 12 12 
>95 6 6 
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SPIROMETRIC VALUES 
FEV1 and FEV1/FVC are considered as indices of pulmonary function in chronic 
obstructive pulmonary disease. FEV1 - reflects the degree of airway obstruction. FVC - 
Reflect the change in vital capacity. FEV1 / FVC< 70 shows obstructive lung disease. 
  
Table-21:   SEVERITY OF DISEASE IN STUDIED POPULATION     
SEVERITY MALE % FEMALE % TOTAL % 
MILD 0 0 0 0 0 0 
MODERATE 52 56.5 0 0 52 52 
SEVERE 34 37 8 100 42 42 
VERY.SEVERE 6 6.5 0 0 6 6 
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BAR CHART SHOWING SEVERITY OF DISEASE 
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DISCUSSION 
Age 
Most of male patients were between 61-70 years of age constituting 50% and the 
Minimum number cases were in the age group of 81-90 years being 0%. 
 
Among females, number of cases in the age group of 51-60 years constituted 50% and in 
the age group of 71-80 and 81-90 were one case each constituting of 25% each 
respectively. 
 
Both sexes put together the maximum cases were in age group of 61-70 years constitute 
46 % and minimum in the age group of 81-90 years constituting only 2%. 
STUDY 41- 50 51-60 61-70 
Sao paulo (Brazil) 9% 16% 25% 
Santiago (Chile) 8% 14% 30% 
Mexico city (Mexico) 3% 6% 18% 
Montevideo (Uruguay) 5% 14% 32% 
OUR STUDY (TRICHY, INDIA) 8% 26% 46% 
 
With comparison of above studies, our study has highest percentage of COPD cases in 
61-70 year age group. 
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SEX  
92 percent of cases were male patients, females were 8 cases and 8 percent 
STUDY  POPULATION MALE, FEMALE RATIO 
 Radha (1977)  New Delhi 1.8 
 Thiruvengadam (1977)  Madras 1.6 
 Viswanathan (1966)  Patna 1.6 
OUR STUDY TRICHY 11.5 
While comparison with, Our study has highest percentage of COPD cases in males 
RURAL URBAN DISTRIBUTION 
Our study shows 38 cases in rural area, 62 cases in urban population with 38% 1nd 62% 
respectively.  
STUDY POPULATION RURAL, URBAN RATIO  
 Viswanathan (1977)  Delhi  0.67 
 Malik (1986)  North India 2.6 
 Jindal (1993)  North India  1.77 
OUR STUDY TRICHY 0.61 
 
While comparing above studies, our study has lowest rural urban population ratio. 
OCCUPATION 
In this study group majority of the patients were non - agricultural coolies 
accounting to 54%. The remaining were businessmen and agriculture 20% each. House 
wives were accounting for 8%. 
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SMOKING 
In our study out of 92 male patients 86 were smokers. In females 8 out 8 were non-
smokers. Smoker, non smoker ratio is 6.1, it is much higher than other studies  
STUDY POPULATION SMOKER, NON-SMOKER 
RATIO 
 Wig (1964)  Delhi 2.0 
 Sikand (1966)  Delhi 2.5 
 Ray (1995)  South India 1.6 
OUR STUDY TRICHY 6.1 
 
 
PRESENTING SYMPTOMS 
In the present study, cough and dyspnoea were present in all the cases and expectoration 
was present in 96% of cases, wheezing was present in 62% and fever was present only in 
12% cases. It correlates with most of similar studies. 
 
PHYSICAL SIGNS 
In the present study, most of patients presented with obesity, short neck and Nicotine 
stain in lips, and very few had cyanosis. Some of patients were clinically pallor.  
. 
RESPIRATORY SIGNS 
In the present study majority of patients had crepitations and rhonchi and few patients 
had barrel shaped chest. 
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CHEST X-RAY 
In the present study x-ray showed features of emphysema in 24 cases, features of chronic 
bronchitis in 20 cases & both emphysematous, bronchitis changes in 32 cases. 22 cases 
(22%) had no findings in x-ray chest. 
 
ECG FINDINGS 
In this study, 26 patients, i.e. 26% of patients have normal findings. 30 cases(30%) have 
sinus tachycardia. Non progression R wave in V1-V3 accounts for 26% i.e 26 cases. Lead 
1 sign is just 4% of cases. Persistent of S wave in V5-V5 accounts for 18%. 
 
So, general examination, complete systemic examination, chest x-ray and ECG need not 
to have findings in COPD patients. 
 
HEMOGLOBIN 
Most of the patients have below normal or near normal values. No case has the 
polycythemic range of Hemoglobin values. This may be due to malnutrition. 
 
HEMATOCRIT 
In this study 86% patients have less than 40% Hematocrit. 
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No single patient has value of polycythemia range. This may be due to other systemic 
causes. 
In the study by Claudia Cote, MD, Marya Zilberberg, MD et al polycythemia was present 
in 5% of patients. In another study by C. Cote, S. H. Mody et al, polycythemia was 
present in 6% of cases. 
 
PULSE OXIMETRY 
 
In this study 20 cases (20 percent) have oxygen saturation less than 89%. Most of patients 
have 89-92% oxygen saturation. 6 patients have more than 95% SaO2. 
 
SPIROMETRY 
52% of patients were fall on moderate COPD, 42% were in severe COPD range. Only 
6% of patients were in very severe range of COPD. Nobody was in mild   COPD. This 
may be due to the study was conducted in inpatients who were admitted symptomatic. 
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CONCLUSIONS 
 
• Majority of the patients were in the age group of 61-70 years. COPD was seen 
predominantly in male patients and majorities were smokers who have more than 
20 smoke pack years. 
• Because of urbanization, prevalence of COPD increasing in urban.  
• In the majority of patients the duration of illness was 2-5 years. Cough and 
breathlessness were present in all patients. 
• Wheeze is not the predominant symptoms in routine COPD patients. 
• Diminished chest movements, crepitations, rhonchi, were present in majority of 
patients. 
• As the number of cigarettes/day and duration increases the severity of the disease 
also increases in the studied population. 
• In females exposure to smoke due to burnt fuel is the risk factor. 
• In the study, about 40 % of cases were in stage III disease. 
• As the severity & duration of the disease increases they are more prone to develop 
hypoxia and polycythemia as a complication. In our study 8 patients had hypoxia, 
as assessed by pulse oximetry, but no patient was in polycythemic range of 
hemoglobin or hematocrit values, this may be due to malnutrition. 
• Clinical examination, ECG and chest X-ray may be normal in COPD patients. So 
diagnosis and severity should be based on Pulmonary Function Test. 
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• Pulse Oximetry is the best bedside tool to assess the hypoxemia in COPD patients 
and very useful to oxygen therapy. 
• Spirometry is the definitive and gold standard investigation for diagnosis of 
chronic obstructive pulmonary disease, assess the severity of disease, reversibility 
and follow up. 
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PROFORMA 
‘An analysis of ECG, chest x-ray, pulmonary function tests, Pulse oximetry and 
Haematocrit abnormalities in chronic obstructive pulmonary disease patients’ 
I. Name  
2. Age& Sex 
3. IP NO 
4. Occupation 
5. Address  
6. Presenting complaints 
 
7. History of present illness 
a. Cough-Duration/Dry or Productive If productive colour/odor/Quantity/Type Diurnal / 
seasonal / postural variation 
b.Breathlessness- Duration/ Relation to exertion /variation/ Precipitating 
actors/PND,Orthopnoea 
c. Wheezing Duration/Precipitating factors/Duration of attacks  
d. Chest pain-Duration/Onset/Location/Nature/Radiation/Aggravating& Relieving factors 
e. Hemoptysis-Duration/Quantity 
f. Fever-Duration/Degree/Type/Association 
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8. Past history - Similar complaints / tuberculosis / asthma/ allergy / epilepsy / cardiac 
illness / diabetes mellitus/ hypertension 
9. Personal history-Tobacco chewing/ Tobacco smoking-Pack years/Occupational 
exposure - Dust / fumes / smoke / chemicals 
10. Family history-Tuberculosis/Bronchial asthma/Allergy like utricaria 
Rhinitis / eczema 
11. General Examination-Comfortable /dyspnoeic/Built/Nourishment/ 
Pallor/Cyanosis/Icterus/Clubbing/Oedema/Lymphadenopathy 
12. Vitals-Pulse/BP/Respiration Rate/Pursed lip breathing 
13. Respiratory system 
Inspection-Shape of the chest/deformity/tracheal position/apex& other pulsations/ 
veins/Chest movement  
Palpation-trachealposition/apex/chest movement/Vocal fremitus tenderness/Chest 
measurements  
Percussion-note/Liver dullness  
Auscultation-Breath sounds/Rhonchi/Crepitations/Pleural rub Vocal resonance 
14. Other systems 
15. Investigations 
a) Hemoglobin/Red cell count/Differential count/ESR/ Haematocrit/ Random blood 
sugar/Urea/Creatinine 
b) chest x-ray/ECG 
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c) Pulse oximetry- oxygen saturation/Pulmonary function tests FEV1, FVC, and 
FEV1/FVC after bronchodilation 
16.Diagnosis 
Treatment: Comments 
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